- Home
- IGMS vs SILC Comparison
IGMS vs SILC Comparison
Compare IGMS & SILC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- SILC
- Stock Information
- Founded
- IGMS 1993
- SILC 1987
- Country
- IGMS United States
- SILC Israel
- Employees
- IGMS N/A
- SILC N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- SILC Computer Manufacturing
- Sector
- IGMS Health Care
- SILC Technology
- Exchange
- IGMS Nasdaq
- SILC Nasdaq
- Market Cap
- IGMS 82.1M
- SILC 83.2M
- IPO Year
- IGMS 2019
- SILC 1994
- Fundamental
- Price
- IGMS $1.17
- SILC $15.26
- Analyst Decision
- IGMS Hold
- SILC Hold
- Analyst Count
- IGMS 8
- SILC 2
- Target Price
- IGMS $6.00
- SILC N/A
- AVG Volume (30 Days)
- IGMS 211.8K
- SILC 9.0K
- Earning Date
- IGMS 08-13-2025
- SILC 07-28-2025
- Dividend Yield
- IGMS N/A
- SILC N/A
- EPS Growth
- IGMS N/A
- SILC N/A
- EPS
- IGMS N/A
- SILC N/A
- Revenue
- IGMS $2,681,000.00
- SILC $58,134,000.00
- Revenue This Year
- IGMS $134.30
- SILC $6.26
- Revenue Next Year
- IGMS $22.37
- SILC $19.14
- P/E Ratio
- IGMS N/A
- SILC N/A
- Revenue Growth
- IGMS 27.36
- SILC N/A
- 52 Week Low
- IGMS $0.92
- SILC $11.35
- 52 Week High
- IGMS $22.50
- SILC $18.24
- Technical
- Relative Strength Index (RSI)
- IGMS 42.70
- SILC 59.12
- Support Level
- IGMS $1.17
- SILC $14.55
- Resistance Level
- IGMS $1.40
- SILC $15.50
- Average True Range (ATR)
- IGMS 0.07
- SILC 0.51
- MACD
- IGMS -0.01
- SILC 0.05
- Stochastic Oscillator
- IGMS 4.17
- SILC 100.00
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.